ASCO 2019 annual meeting
Programme du congrès
Lieu : Chicago, IL
Pays : Etats-Unis
Langue : ENG
Date de début :
Date de fin :
Spécialités : Oncologie
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity
- Date : 31/05/2019
- 4 0
ABC-06 trial results: Second-line ASC+mFOLFOX chemotherapy for suitable patients
- Date : 31/05/2019
- 2 0
Enzalutamide as treatment for men with mHSPC who have received testosterone suppression
- Date : 31/05/2019
- 2 0
FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma
- Date : 31/05/2019
- 1 0
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer
- Date : 31/05/2019
- 1 0
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1
- Date : 31/05/2019
- 0 0
Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer
- Date : 31/05/2019
- 0 0
Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients
- Date : 31/05/2019
- 0 0
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression
- Date : 31/05/2019
- 0 0
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
- Date : 31/05/2019
- 0 0
Long-term survival after laparoscopic versus open resection for colorectal liver metastases
- Date : 31/05/2019
- 0 0
A study of KTE-C19 in adults with relapsed/refractory acute lymphoblastic leukaemia
- Date : 31/05/2019
- 0 0
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations
- Date : 31/05/2019
- 0 0
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
- Date : 31/05/2019
- 0 0
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA
- Date : 31/05/2019
- 0 0
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
- Date : 31/05/2019
- 0 0
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC
- Date : 31/05/2019
- 0 0
Ado-trastuzumab emansine in patients with HER2 amplified salivary gland cancers
- Date : 31/05/2019
- 0 0
Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2
- Date : 31/05/2019
- 0 0
Guiding treatment decisions through the use of molecular profiling in breast cancer
- Date : 31/05/2019
- 0 0
Preventing brain metastases in patients with HER2+ or triple negative breast cancer
- Date : 31/05/2019
- 0 0
Subcutaneous versus intravenous daratumumab administration in patients with relapsed
- Date : 31/05/2019
- 0 0
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy
- Date : 31/05/2019
- 0 0
The success of immunotherapy means we have to change our mindset as we treat patients
- Date : 31/05/2019
- 0 0
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients
- Date : 31/05/2019
- 0 0
The use of CDK 4/6 inhibitors now translates to a significant survival benefit
- Date : 31/05/2019
- 0 0
Sélection de congrès
14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024
- Date : 12/12/2024
-
2514
0
45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024
- Date : 06/11/2024
-
5215
0